NantKwest, Inc. Business Finance Contracts & Agreements
48 Contracts & Agreements
- Assignment Agreements (2 contracts)
- Note Agreements (21)
- Purchase Agreements (7)
- Registration Rights Agreements (4)
- Security Agreements (1)
- Stock Agreements (3)
- Underwriting Agreements (2)
- Warrant Agreements (8)
- Amended and Restated Promissory Note between ImmunityBio, Inc. and Nant Capital, LLC dated December 29, 2023 (Filed With SEC on March 19, 2024)
- Letter Amendment dated December 29, 2023 to the Convertible Promissory Notes dated March 31, 2023 (as amended on September 11, 2023) and September 30, 2023 issued by ImmunityBio,... (Filed With SEC on March 19, 2024)
- Stock Purchase and Option Agreement dated December 29, 2023 by and between the Investors and ImmunityBio, Inc (Filed With SEC on March 19, 2024)
- Security and Pledge Agreement as of December 29, 2023 among ImmunityBio, Inc., the Subsidiary Guarantors listed on the signature pages hereto, such other parties that may become... (Filed With SEC on March 19, 2024)
- Revenue Interest Purchase Agreement dated as of December 29, 2023 among ImmunityBio, Inc., the Purchasers from time to time party hereto and Infinity SA LLC (Filed With SEC on March 19, 2024)
- Convertible Promissory Note dated (Filed With SEC on November 9, 2023)
- Stock Purchase Agreement (Filed With SEC on November 9, 2023)
- Amended Form of February 2023 Common Stock Purchase Warrant (Filed With SEC on November 9, 2023)
- Securities Purchase Agreement, dated as of July 20, 2023 (Filed With SEC on July 21, 2023)
- Form of Common Stock Purchase Warrant (Filed With SEC on July 21, 2023)
- Promissory Note between ImmunityBio, Inc. and Nant Capital, LLC dated June 1 (Filed With SEC on June 14, 2023)
- Convertible Promissory Note by and between the Company and Nant Capital, LLC dated as of March 31, 2023 (Filed With SEC on March 31, 2023)
- Securities Purchase Agreement dated as of February 15, 2023 (Filed With SEC on February 15, 2023)
- Form of Common Stock Purchase Warrant (Filed With SEC on February 15, 2023)
- Promissory Note between the Company and Nant Capital, LLC dated December 12, 2022 (Filed With SEC on December 12, 2022)
- Securities Purchase Agreement dated as of December 12, 2022 (Filed With SEC on December 12, 2022)
- Form of Common Stock Purchase Warrant (Filed With SEC on December 12, 2022)
- Second Amended and Restated Convertible Promissory Note between ImmunityBio, Inc. and NantMobile, LLC dated August 31, 2022 (Filed With SEC on November 9, 2022)
- Second Amended and Restated Convertible Promissory Note between ImmunityBio, Inc. and NantCancerStemCell, LLC dated August 31, 2022 (Filed With SEC on November 9, 2022)
- Second Amended and Restated Convertible Promissory Note between ImmunityBio, Inc. and NantWorks, LLC dated August 31, 2022 (Filed With SEC on November 9, 2022)
- Second Amended and Restated Convertible Promissory Note between ImmunityBio, Inc. and Nant Capital, LLC dated August 31, 2022 (Filed With SEC on November 9, 2022)
- Amended and Restated Convertible Promissory Note between ImmunityBio, Inc. and Nant Capital, LLC dated August 31, 2022 (Filed With SEC on November 9, 2022)
- Amended and Restated Convertible Promissory Note between ImmunityBio, Inc. and Nant Capital, LLC dated August 31, 2022 (Filed With SEC on November 9, 2022)
- Amended and Restated Promissory Note between ImmunityBio, Inc. and Nant Capital, LLC dated August 31, 2022 (Filed With SEC on November 9, 2022)
- Promissory Note between ImmunityBio, Inc. and Nant Capital, LLC dated August 31, 2022 (Filed With SEC on November 9, 2022)
- Purchase Agreement, by and between Athenex, Inc. and ImmunityBio, Inc. dated as of January 7, 2022 (Filed With SEC on January 12, 2022)
- Promissory Note by and between the Company and Nant Capital, LLC dated as of December 17, 2021 (Filed With SEC on December 20, 2021)
- Membership Interest Purchase Agreement entered into as of September 27, 2021, by and among Nant Capital, LLC and ImmunityBio, Inc (Filed With SEC on November 12, 2021)
- Promissory Note, dated February 22, 2021, issued by NantCell, Inc. (f/k/a ImmunityBio, Inc.) to Nant Capital, LLC (Filed With SEC on March 10, 2021)
- Common Stock Purchase Agreement, dated April 30, 2018, by and among ImmunityBio, Inc. and NantBio, Inc (Filed With SEC on January 19, 2021)
- Assignment Agreement, dated July 2, 2017, by and between NantPharma, LLC and Immunotherapy NANTibody, LLC (Filed With SEC on January 19, 2021)
- Assignment Agreement, dated July 31, 2017, by and between ImmunityBio, Inc. and NantOmics, LLC (Filed With SEC on January 19, 2021)
- Common Stock Purchase Warrant, dated June 30, 2016, issued by ImmunityBio, Inc. to NantWorks, LLC (Filed With SEC on January 19, 2021)
- Promissory Note, dated September 30, 2020, issued by ImmunityBio, Inc. to Nant Capital, LLC (Filed With SEC on January 19, 2021)
- Amended and Restated Promissory Note, dated July 28, 2020, issued by ImmunityBio, Inc. to NantMobile, LLC (Filed With SEC on January 19, 2021)
- Amended and Restated Promissory Note, dated July 28, 2020, issued by ImmunityBio, Inc. to NantCancerStemCell, LLC (Filed With SEC on January 19, 2021)
- Amended and Restated Promissory Note, dated July 28, 2020, issued by ImmunityBio, Inc. to NantWorks, LLC (Filed With SEC on January 19, 2021)
- Amended and Restated Promissory Note, dated July 28, 2020, issued by ImmunityBio, Inc. to Nant Capital, LLC (Filed With SEC on January 19, 2021)
- Underwriting Agreement, dated June 24, 2020 (Filed With SEC on June 25, 2020)
- NANTKWEST, INC. [ ] Shares of Common Stock, par value $0.0001per share Underwriting Agreement (Filed With SEC on July 16, 2015)
